Key Inclusion Criteria:

          -  Male and female adult patients at least 18 years of age on day of signing informed
             consent

          -  Histologically confirmed non-small cell lung cancer (NSCLC) adenocarcinoma

          -  Advanced (stage IIIb) disease that is not amenable to curative intent treatment with
             concurrent chemoradiation and metastatic (stage IV) patients

          -  Progressed clinically and/or radiographically per RECIST v1.1 after receiving a PD-1
             or PD-L1 antagonist for a minimum of 12 weeks

          -  Measurable disease per RECIST v1.1

          -  Disease that can be safely accessed via bronchoscopic, thoracoscopic or percutaneous
             biopsy for multiple core biopsies and participant is willing to provide tissue from
             newly obtain biopsies on study in a subgroup of patients

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Adequate organ function

          -  Highly effective birth control

          -  Able to swallow and absorb oral tablets

        Key Exclusion Criteria:

          -  Current use of NSAIDs, COX-2 inhibitors

          -  Known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS
             gene alteration

          -  No history of smoking (≤100 cigarettes lifetime)

          -  History of severe hypersensitivity reactions to a PD-1/L1 antibody

          -  Received prior systemic anti-cancer therapy including investigational agents within 4
             weeks prior to treatment or 5 half-lives, whichever is shorter

          -  Received prior radiotherapy within 2 weeks of start of study treatment

          -  Has received a live vaccine within 30 days prior to the first dose of study treatment

          -  Taking strong CYP3A4 or P-glycoprotein inhibitors or inducers

          -  Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior the first dose of study
             treatment

          -  Known additional malignancy that is progressing or has required active treatment
             within the past 3 years (with some permitted exceptions)

          -  Known active CNS metastases and/or carcinomatous meningitis

          -  Active autoimmune disease that has required systemic treatment in past 2 years

          -  History of pneumonitis that required steroids or has current pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Recent or current GI ulcer, colitis or non-immune colitis

          -  Known history of human immunodeficiency virus (HIV) infection, or known active
             Hepatitis B, or Hepatitis C virus infection

          -  Has had an allogeneic tissue/solid organ transplant

          -  Clinically significant (i.e.active) cardiovascular disease